| Literature DB >> 28081969 |
Sylvie Morgeaux1, Bertrand Poirier2, C Ian Ragan3, Dianna Wilkinson4, Ulrich Arabin5, Françoise Guinet-Morlot6, Robin Levis7, Heidi Meyer8, Patrice Riou6, Shahjahan Shaid5, Dmitriy Volokhov7, Noël Tordo9, Jean-Michel Chapsal10.
Abstract
Three different ELISAs quantifying rabies glycoprotein were evaluated as in vitro alternatives to the National Institutes of Health (NIH) in vivo potency test for batch release of human rabies vaccines. The evaluation was carried out as an international collaborative study supported by the European Partnership for Alternatives to Animal Testing (EPAA). This pre-validation study, the results of which are presented in this paper, compared three different ELISA designs, assessing their within- and between-laboratory precision. One of the ELISA designs was proposed to the European Directorate for the Quality of Medicines & HealthCare (EDQM) and accepted for an international collaborative study under the umbrella of the Biological Standardisation Programme.Entities:
Keywords: ELISA; Human; In vitro; NIH test; Rabies; Vaccine
Mesh:
Substances:
Year: 2017 PMID: 28081969 DOI: 10.1016/j.vaccine.2016.12.039
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641